Matthias Egger

5.2k total citations · 3 hit papers
42 papers, 1.1k citations indexed

About

Matthias Egger is a scholar working on Epidemiology, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Matthias Egger has authored 42 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Epidemiology, 23 papers in Infectious Diseases and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matthias Egger's work include Antifungal resistance and susceptibility (23 papers), Fungal Infections and Studies (21 papers) and Gastric Cancer Management and Outcomes (9 papers). Matthias Egger is often cited by papers focused on Antifungal resistance and susceptibility (23 papers), Fungal Infections and Studies (21 papers) and Gastric Cancer Management and Outcomes (9 papers). Matthias Egger collaborates with scholars based in Austria, United States and Germany. Matthias Egger's co-authors include Martin Hoenigl, Jeffrey D. Jenks, George R. Thompson, Robert Krause, Juergen Prattes, Oliver A. Cornely, Amir Arastehfar, Rosanne Sprute, Nathan P. Wiederhold and Cornelia Lass‐Flörl and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Matthias Egger

41 papers receiving 1.1k citations

Hit Papers

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olo... 2021 2026 2022 2024 2021 2023 2024 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
    2021 283 citations Martin Hoenigl, Rosanne Sprute et al. Drugs profile →
  2. Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap
    2023 125 citations Farnaz Daneshnia, João Nóbrega de Almeida et al. The Lancet Microbe profile →
  3. Impact of climate change and natural disasters on fungal infections
    2024 83 citations Danila Seidel, Sebastian Wurster et al. The Lancet Microbe profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthias Egger Austria 19 801 682 112 104 85 42 1.1k
Zekaver Odabaşı Türkiye 14 1.1k 1.3× 714 1.0× 120 1.1× 80 0.8× 71 0.8× 33 1.3k
Peter‐Michael Rath Germany 20 640 0.8× 635 0.9× 148 1.3× 76 0.7× 95 1.1× 73 1.2k
José María Aguado Spain 18 1.0k 1.3× 863 1.3× 73 0.7× 96 0.9× 39 0.5× 34 1.2k
Florence Persat France 20 796 1.0× 648 1.0× 106 0.9× 87 0.8× 102 1.2× 64 1.3k
Jong Hee Shin South Korea 21 699 0.9× 603 0.9× 145 1.3× 53 0.5× 80 0.9× 71 1.2k
Marilena La Sorda Italy 16 1.1k 1.3× 869 1.3× 113 1.0× 99 1.0× 94 1.1× 31 1.4k
Karine Sitbon France 13 1.3k 1.6× 1.2k 1.7× 156 1.4× 88 0.8× 57 0.7× 15 1.5k
Jürgen Held Germany 18 570 0.7× 550 0.8× 98 0.9× 79 0.8× 67 0.8× 54 1.1k
Themistoklis Kourkoumpetis United States 15 481 0.6× 494 0.7× 107 1.0× 41 0.4× 63 0.7× 24 858
Pirkko Koukila-Kähkölä Finland 15 625 0.8× 607 0.9× 141 1.3× 85 0.8× 120 1.4× 24 1.0k

Countries citing papers authored by Matthias Egger

Since Specialization
Citations

This map shows the geographic impact of Matthias Egger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Egger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Egger more than expected).

Fields of papers citing papers by Matthias Egger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthias Egger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Egger. The network helps show where Matthias Egger may publish in the future.

Co-authorship network of co-authors of Matthias Egger

This figure shows the co-authorship network connecting the top 25 collaborators of Matthias Egger. A scholar is included among the top collaborators of Matthias Egger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthias Egger. Matthias Egger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Egger, Matthias, Karl Dichtl, Juergen Prattes, et al.. (2024). Performance of the clarus Aspergillus galactomannan enzyme immunoassay prototype for the diagnosis of invasive pulmonary aspergillosis in serum. Mycoses. 67(6). e13756–e13756. 3 indexed citations
3.
Egger, Matthias, et al.. (2024). Climate Change and Medical Mycology. Infectious Disease Clinics of North America. 39(1). 1–22. 4 indexed citations
4.
Seidel, Danila, Sebastian Wurster, Jeffrey D. Jenks, et al.. (2024). Impact of climate change and natural disasters on fungal infections. The Lancet Microbe. 5(6). e594–e605. 83 indexed citations breakdown →
5.
Egger, Matthias, et al.. (2024). New treatment options for critically important WHO fungal priority pathogens. Clinical Microbiology and Infection. 31(6). 922–930. 32 indexed citations
6.
Jenks, Jeffrey D., Juergen Prattes, Sebastian Wurster, et al.. (2023). Social determinants of health as drivers of fungal disease. EClinicalMedicine. 66. 102325–102325. 30 indexed citations
7.
Feys, Simon, et al.. (2023). Treatment of Invasive Aspergillosis: How It’s Going, Where It’s Heading. Mycopathologia. 188(5). 667–681. 27 indexed citations
8.
Egger, Matthias, Angela Horvath, Florian Prüller, et al.. (2023). Fungal translocation measured by serum 1,3‐ß‐D‐glucan correlates with severity and outcome of liver cirrhosis—A pilot study. Liver International. 43(9). 1975–1983. 10 indexed citations
9.
Jenks, Jeffrey D., Mohanad Al‐Obaidi, Matthias Egger, et al.. (2023). Race and ethnicity: Risk factors for fungal infections?. PLoS Pathogens. 19(1). e1011025–e1011025. 27 indexed citations
10.
Hoenigl, Martin, Jeffrey D. Jenks, Matthias Egger, Márcio Nucci, & George R. Thompson. (2023). Treatment of Fusarium Infection of the Central Nervous System: A Review of Past Cases to Guide Therapy for the Ongoing 2023 Outbreak in the United States and Mexico. Mycopathologia. 188(6). 973–981. 18 indexed citations
11.
Egger, Matthias, et al.. (2023). Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations. Infection and Drug Resistance. Volume 16. 2167–2178. 18 indexed citations
12.
Daneshnia, Farnaz, João Nóbrega de Almeida, Macit İlkit, et al.. (2023). Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap. The Lancet Microbe. 4(6). e470–e480. 125 indexed citations breakdown →
13.
Semmler, Georg, Sarah Wernly, Bernhard Wernly, et al.. (2021). Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—Rather a Bystander Than a Driver of Mortality. The Journal of Clinical Endocrinology & Metabolism. 106(9). 2670–2677. 34 indexed citations
14.
Hoenigl, Martin, Rosanne Sprute, Matthias Egger, et al.. (2021). The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. 81(15). 1703–1729. 283 indexed citations breakdown →
15.
Egger, Matthias, Peter Briza, Danila Zennaro, et al.. (2019). Similar Allergenicity to Different Artemisia Species Is a Consequence of Highly Cross-Reactive Art v 1-Like Molecules. Medicina. 55(8). 504–504. 14 indexed citations
16.
Trobisch, Andreas, Gregor Gorkiewicz, Herwig Lackner, et al.. (2019). Invasive mucormycosis during treatment for acute lymphoblastic leukaemia—successful management of two life-threatening diseases. Supportive Care in Cancer. 28(5). 2157–2161. 3 indexed citations
17.
18.
Schmalenberg, Harald, Salah‐Eddin Al‐Batran, Claudia Pauligk, et al.. (2017). CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach. Journal of Cancer Research and Clinical Oncology. 144(3). 559–569. 5 indexed citations
19.
20.
Egger, Matthias, Florian Prüller, Reinhard B. Raggam, et al.. (2017). False positive serum levels of (1–3)-ß-D-Glucan after infusion of intravenous immunoglobulins and time to normalisation. Journal of Infection. 76(2). 206–210. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zekaver Odabaşı Breakdown of academic impact, for papers by Peter‐Michael Rath Breakdown of academic impact, for papers by José María Aguado Breakdown of academic impact, for papers by Florence Persat Breakdown of academic impact, for papers by Jong Hee Shin Breakdown of academic impact, for papers by Marilena La Sorda Breakdown of academic impact, for papers by Karine Sitbon Breakdown of academic impact, for papers by Jürgen Held Breakdown of academic impact, for papers by Themistoklis Kourkoumpetis Breakdown of academic impact, for papers by Pirkko Koukila-Kähkölä
Rankless by CCL
2026